Posted in News
DOSE BANDED CHEMOTHERAPY
Since late October, dm+d has resumed authoring chemotherapy drugs in bags and syringes that are in compliance with the dose banding tables. Although these are not yet a complete set, commonly used doses for bortezomib, cisplatin, cyclophosphamide and fluorouracil have been authored. Trust drug lines that are an exact match for the authored products have been mapped to these and are included in the Tag for Dose Band Compliant Chemotherapy.
MEROPENEM WITH VABORBACTAM
A new product has recently been launched in the UK that contain meropenem combined with the beta-lactamase inhibitor vaborbactam (Vaborem®). This product was added to dm+d in late November so it is available to search and add to reports in Define although no DDD is available as of yet.
Olaratumab (Lartruvo) was indicated for soft tissue sarcoma and had been included in earlier iterations of the Cancer Drugs Fund and NICE TA465, pending the results of a further clinical trial.
In July 2019, the results from a clinical trial indicated that the risk/benefit profile for olaratumab was negative and the EMA withdrew its marketing authorisation.
Within Define, the NICE TA has been marked as rescinded but it is retained within the historic Cancer Drugs Fund Tags so users can determine if it had been used in their Trust here.